Medtronic and Abbott Laboratories on Monday both highlighted the advantages of their respective drug-coated stents compared with Boston Scientific Corp.'s best-selling Taxus stent. One study showed that Medtronic's Endeavor was found to keep clogged arteries open for up to one year as well as Taxus and that its patients had fewer heart complications. Other data showed Abbott's Xience was able to lower the risk of heart attack, repeat surgery and death by 43% compared with Boston Scientific's stent.

Related Summaries